Trial Profile
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms ENSIGN
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 Dec 2023 Results of analysis assessing impact of CAR persistence and B cell aplasia on duration of remission based on long term follow up data from pivotal phase II studies in patents with r/r ALL (ELIANA, ENSIGN, NCT03123939, NCT01626495), r/r DLBCL (JULIET), and r/r FL (ELARA), along with the long term follow up study (NCT02445222) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 07 Dec 2023 According to a BostonGene media release, data from this trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023.
- 09 Nov 2022 Results (n=206) assessing the influence of household poverty and neighborhood social determinants on outcomes from CAR T-cell therapy for relapsed/refractory leukemia from (NCT01626495; NCT02435849 ; NCT02374333; NCT02228096; NCT02906371) clinical trials and commercial tisagenlecleucel from 2012 to 2020, published in the Blood.